The vaccine from the North American laboratory Moderna will be included in the federal study carried out by our country to evaluate the combination of doses in the same scheme of drugs against the coronavirus, the Ministry of Health reported yesterday.
The research aims to evaluate the efficacy and safety of the use of two different doses of vaccines against the SARS-CoV-2 virus, and also to compare the results of heterologous and homologous vaccination schedules.
It would be one of the options to cover the lack of the second compound of the Russian vaccine Sputnik V, which is still awaited by more than 6 million Argentines.
“The objective of the study is to have national evidence for decision-making based on the analysis of immunogenicity and safety of the use of different doses in the same scheme of the vaccines available at the moment in the country: AstraZeneca, Moderna, Sinopharm and Sputnik -V ”, they detailed from the Ministry of Health.
“Advancing in the production of scientific evidence in this regard is very important in order to have a greater range of possibilities to achieve complete schemes in the shortest time possible,” explained the Minister of Health, Carla Vizzotti.
The study to evaluate the combination of vaccines against the coronavirus is open, collaborative and federal. Researchers from the Coronavirus Unit of the Ministry of Science, Technology and Innovation participate in it; of the Conicet; and from the provinces of Buenos Aires, Córdoba, La Rioja, Mendoza and San Luis.
The research includes volunteers over 18 years of age vaccinated with a dose of Sputnik V, AstraZeneca or Sinopharm vaccine up to 60 days prior to their enrollment, with and without identified risk factors for Covid who remain in the jurisdiction where their study began until end of it.
People with immunocompromise due to underlying disease or immunosuppressive treatment are excluded; pregnant and lactating people, who are registered in the Argentine Integrated Health Information System for having suffered from coronavirus (symptomatic or asymptomatic); and those who have had a severe allergic reaction (anaphylaxis) to any vaccine.
Models based on heterologous immunization schemes with vaccines from different platforms need to be evaluated through clinical trials to show whether they have a similar response to already established homologous schemes. This is achieved through the comparative evaluation of its immunogenicity and reactogenicity (adverse events) with studies that consider implementation possibilities, are adaptive and respond to real-life situations.
The Ministry of Health proposed the development of a collaborative network for the integration of studies on vaccination strategies against Covid with the use of heterologous schemes from the evaluation of non-inferiority of these against homologous vaccination schemes already implemented worldwide.
According to the WHO, mRNA-1273, that is, Moderna’s vaccine, offers an efficacy of 94.1% when the two doses are administered. This high efficacy was maintained in all age groups above 18 years and was not affected by the sex or ethnicity of the population.